Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes

Journal of Lipid Research

Volumn 49, Issue 8, 2008, Pages 1746-1751

  Cabré, Anna ^a   Lázaro, Iolanda ^a   Girona, Josefa ^a   Manzanares, Josep Maria ^a   Marimón, Francesc ^a   Plana, Núria ^a   Heras, Mercedes ^a   Masana, Lluís ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Insulin; Lipids; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

ADULT; AGE; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; BLOOD; FEMALE; LIPID METABOLISM; MIDDLE AGED;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED;

EID: 51449110846     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800102-JLR200     Document Type: Article

References (27)

1. Taskinen, M. R. 2003. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 46: 733-749.
2. McTernan, P. G., A. L. Harte, L. A. Anderson, A. Green, S. A. Smith, J. Holder, A. H. Barnett, M. C. Eggo, and S. Kumar. 2002. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes. 51: 1493-1498.
3. Adiels, M., M. R. Taskinen, C. Packard, M. J. Caslake, A. SoroPaavonen, J. Westerbacka, S. Vehkavaara, A. Hakkinen, S. O. Olofsson, H. Yki-Jarvinen, et al. 2006. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 49: 755-765.
4. Kershaw, E. E., and J. S. Flier. 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89: 2548-2556.
5. Lau, D. C., B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma. 2005. Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. 288: H2031-H2041.
6. Xu, A., Y. Wang, J. Y. Xu, D. Stejskal, S. Tam, J. Zhang, N. M. Wat, W. K. Wong, and K. S. Lam. 2006. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52: 405-413.
7. Stejskal, D., and M. Karpisek. 2006. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur. J. Clin. Invest. 36: 621-625.
8. Xu, A., A. W. K. Tso, B. M. Y. Cheung, Y. Wang, N. M. S. Wat, C. H. Y. Fong, D. C. Y. Yeung, E. D. Janus, P. C. Sham, and K. S. L. Lam. 2007. Circulating adipocyte - fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 115: 1537-1543.
9. Cabre, A., I. Lazaro, J. Girona, J. M. Manzanares, F. Marimón, N. Plana, M. Heras, and L. Masana. 2007. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 195: e150-e158.
10. Coe, N. R., M. A. Simpson, and D. A. Bernlohr. 1999. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J. Lipid Res. 40: 967-972.
11. Hertzel, A. V., L. A. Smith, A. H. Berg, G. W. Cline, G. I. Shulman, P. E. Scherer, and D. A. Bernlohr. 2006. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am. J. Physiol. Endocrinol. Metab. 290: E814-E823.
12. Flower, D. R., A. C. North, and C. E. Sansom. 2000. The lipocalin protein family: structural and sequence overview. Biochim. Biophys. Acta. 1482: 9-24.
13. Peters, A. L., and D. L. Schriger. 1998. The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors. Am. J. Med. 105: 15S-19S.
14. Schumaker, V. N., and D. L. Puppione. 1986. Sequential flotation ultracentrifugation. Methods Enzymol. 128: 155-170.
15. von Eynatten, M., A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher. 2006. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin. Chem. 52: 853-859.
16. Okada, T., E. Saito, Y. Kuromori, M. Miyashita, F. Iwata, M. Hara, and K. Harada. 2006. Relationship between serum adiponectin level and lipid composition in each lipoprotein fraction in adolescent children. Atherosclerosis. 188: 179-183.
17. Kantartzis, K., K. Rittig, B. Balletshofer, J. Machann, F. Schick, K. Porubska, A. Fritsche, H. U. Haring, and N. Stefan. 2006. The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin. Chem. 52: 1934-1942.
18. Xu, S., and P. Venge. 2000. Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta. 1482: 298-307.
19. Wang, Y., K. S. Lam, E. W. Kraegen, G. Sweeney, J. Zhang, A. W. Tso, W. S. Chow, N. M. Wat, J. Y. Xu, R. L. Hoo, et al. 2007. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 53: 34-41.
20. Yang, Q., T. E. Graham, N. Mody, F. Preitner, O. D. Peroni, J. M. Zabolotny, K. Kotani, L. Quadro, and B. B. Kahn. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 436: 356-362.
21. Cabre, A., I. Lazaro, J. Girona, J. M. Manzanares, F. Marimón, N. Plana, M. Heras, and L. Masana. 2007. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J. Intern. Med. 262: 496-503.
22. Fisher, R. M., P. Eriksson, J. Hoffstedt, G. S. Hotamisligil, A. Thorne, M. Ryden, A. Hamsten, and P. Arner. 2001. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 44: 1268-1273.
23. Fu, Y., N. Luo, M. F. Lopes-Virella, and W. T. Garvey. 2002. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis. 165: 259-269.
24. Fu, Y., L. Luo, N. Luo, and W. T. Garvey. 2006. Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis. 188: 102-111.
25. Makowski, L., K. C. Brittingham, J. M. Reynolds, J. Suttles, and G. S. Hotamisligil. 2005. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 280: 12888-12895.
26. Boord, J. B., S. Fazio, and M. F. Linton. 2002. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol. 13: 141-147.
27. Fredenrich, A. 1998. Role of apolipoprotein CIII in triglyceriderich lipoprotein metabolism. Diabetes Metab. 24: 490-495.